Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600321 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
A Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT06600321 is a Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 158 participants, above the 78-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06600321, a Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ALN-BCAT
Study Locations (20)
Other
- Clinical Trial Site - Milan
- Clinical Trial Site - Rozzano
- Clinical Trial Site - Verona
- Clinical Trial Site - Busan
Texas
- Clinical Trial Site - Dallas
- Clinical Trial Site - Houston
- Clinical Trial Site - San Antonio
California
- Clinical Trial Site - La Jolla
- Clinical Trial Site - Los Angeles
New York
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Arizona
- Clinical Trial Site - Phoenix
Florida
- Clinical Trial Site - Jacksonville
Georgia
- Clinical Trial Site - Atlanta
Illinois
- Clinical Trial Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06600321
The ClinicalTrials.gov registry entry for NCT06600321 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (103% higher). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06600321 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06600321 about?
NCT06600321 is a clinical study titled "A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma". The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The pu...
What is the current status of trial NCT06600321?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2024-12-30. Estimated completion is 2027-10-31.
What conditions does trial NCT06600321 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06600321?
The interventions under investigation include: Pembrolizumab (DRUG), ALN-BCAT (DRUG).
Who is sponsoring clinical trial NCT06600321?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600321 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE NOT RECRUITING · Phase 1
-
Siliphos in Advanced Hepatocellular Carcinoma
COMPLETED · Phase 1
Explore more on PlainTrial
Advanced Hepatocellular Carcinoma
All registered trials for this condition
Metastatic Hepatocellular Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.